78
Participants
Start Date
March 31, 2007
Primary Completion Date
December 31, 2008
Study Completion Date
December 31, 2008
Canakinumab (investigational)
Canakinumab was supplied in 6 mL colorless glass vials each containing nominally 150 mg canakinumab (with 20% overfill). The vials were kept at 2-8°C. At the investigator's site, solutions for infusion were prepared depending on the volume and dose administered.
Placebo
Matching placebo was supplied in form of a lyophilized cake (Powder for Solution for Infusion). At the investigator's site, solutions for infusion were prepared depending on the volume and dose administered.
Methotrexate (MTX)
Methotrexate (MTX) was supplied in tablet form, each of 2.5 mg strength.
Arthritis Clinic of Northern Virginia (Dr. Philip Kempf), Arlington
Jacksonville Center for Clinical Research (Dr. Steven Mathews), Jacksonville
Center for Arthritis and Rheumatic Diseases (Dr. Michael Weitz), South Miami
West Broward Rheumatology Associates, Incorporated (Dr. Elias Halpert), Tamarac
Clinic for Rheumatic Diseases (Dr. Richard Jones, III), Tuscaloosa
Rheumatology Associates of Northern Alabama (Dr. William Shergy), Huntsville
Mercy Arthritis and Osteoporosis Center (Dr. Alan Braun), Urbandale
Rockford Orthopedic Associates (Dr. Richard Olson), Rockford
Clayton Medical Research (Dr. Iri Don), Richmond Heights
Westroads Medical Group (Dr. William Palmer), Omaha
Oklahoma Center for Arthritis therapy and Research (Dr. James McKay), Tulsa
John M. Joseph, MD (Dr. John Joseph), Carlton
Southwest Rheumatology, P.A. (Dr. Atul Singhal), Mesquite
MetaClin Research, Incorporated (Dr. Paul Pickrell), Austin
Arizona Arthritis and Rheumatology Research (Dr. Paul Caldron), Paradise Valley
Arthritis Center of Reno (Dr. Malin Prupas), Reno
Arthritis Northwest Rheumatology, PLLC (Dr. Jeffrey Butler), Spokane
Novartis Investigative site, Brussels
Novartis investigative site, Nuremberg
Novartis investigative site, Milan
Novartis Investigative site, Arnhem
Novartis investigative site, Barcelona
Lead Sponsor
Novartis
INDUSTRY